Rampado Riccardo, Crotti Sara, Caliceti Paolo, Pucciarelli Salvatore, Agostini Marco
First Surgical Clinic Section, Department of Surgical, Oncological and Gastroenterological Sciences, University of Padua, Via Nicolò Giustiniani 2, 35128 Padua, Italy.
Nano-Inspired Biomedicine Laboratory, Institute of Paediatric Research- Città della Speranza, Corso Stati Uniti 4, 35127 Padua, Italy.
J Oncol. 2019 Oct 1;2019:2740923. doi: 10.1155/2019/2740923. eCollection 2019.
Colorectal cancer (CRC) is a diffused disease with limited therapeutic options, none of which are often curative. Based on the molecular markers and targets expressed by the affected tissues, numerous novel approaches have been developed to study and treat this disease. In particular, the field of nanotechnology offers an astonishingly wide array of innovative nanovectors with high versatility and adaptability for both diagnosis and therapy (the so called "theranostic platforms"). However, such complexity can make the selection of a specific nanocarrier model to study a perplexing endeavour for the biomedical scientist or clinician not familiar with this field of inquiry. This review offers a comprehensive overview of this wide body of knowledge, in order to outline the essential requirements for the clinical viability evaluation of a nanovector model in CRC. In particular, the differences among the foremost designs, their specific advantages, and technological caveats will be treated, never forgetting the ultimate endpoint for these systems development: the clinical practice.
结直肠癌(CRC)是一种扩散性疾病,治疗选择有限,且往往没有一种能治愈。基于受影响组织表达的分子标志物和靶点,已经开发出许多新方法来研究和治疗这种疾病。特别是,纳米技术领域提供了一系列令人惊叹的创新纳米载体,它们在诊断和治疗方面具有高度的通用性和适应性(即所谓的“治疗诊断平台”)。然而,这种复杂性可能会使不熟悉该研究领域的生物医学科学家或临床医生在选择用于研究的特定纳米载体模型时感到困惑。本综述全面概述了这一广泛的知识体系,以概述结直肠癌中纳米载体模型临床可行性评估的基本要求。特别是,将探讨最主要设计之间的差异、它们的具体优势和技术注意事项,同时始终牢记这些系统开发的最终目标:临床应用。